Rakovina Therapeutics Announces Second Upsizing of Private Placement
July 19 2024 - 9:47AM
Rakovina Therapeutics Inc. (TSX-V: RKV) (the “Company”), a
biopharmaceutical company committed to advancing new cancer
therapies based on novel DNA-damage response technologies, is
pleased to announce, further to the press releases dated May 23,
2024 and June 20, 2024, that to accommodate additional indications
of interest it will upsize the previously announced private
placement of $2.0 million to $2.3 million, subject to TSX Venture
Exchange (TSX-V) approval. The terms of the private placement
otherwise remain unchanged. The Company now anticipates closing the
private placement on or about July 22, 2024.
About Rakovina
Therapeutics Inc.Rakovina
Therapeutics Inc. is focused on the development of new cancer
treatments based on novel DNA-damage response technologies. The
Company has established a pipeline of novel DNA-damage response
inhibitors with the goal of advancing one or more drug candidates
into human clinical trials and obtaining marketing approval for new
cancer therapeutics from Health Canada, the United States Food and
Drug Administration and similar international regulatory agencies.
Further information may be found at
www.rakovinatherapeutics.com.
The TSX-V has neither approved nor disapproved the content of
this press release. Neither the TSX-V nor its Regulation Services
Provider (as that term is defined in policies of the TSX-V) accepts
responsibility for the adequacy or accuracy of this release.
Notice Regarding
Forward-Looking Statements:This
release includes forward-looking statements regarding the Company
and its respective business, which may include, but is not limited
to, statements with respect to the timeline of the private
placement, TSX Venture Exchange approval for the upsizing, the
proposed business plan of the Company and other statements. Often,
but not always, forward-looking statements can be identified by the
use of words such as “plans”, “is expected”, “expects”,
“scheduled”, “intends”, “contemplates”, “anticipates”, “believes”,
“proposes” or variations (including negative variations) of such
words and phrases, or state that certain actions, events, or
results “may”, “could”, “would”, “might” or “will” be taken, occur
or be achieved. Such statements are based on the current
expectations of the management of the Company. The forward-looking
events and circumstances discussed in this release may not occur by
certain specified dates or at all and could differ materially as a
result of known and unknown risk factors and uncertainties
affecting the Company, including risks regarding the medical device
industry, economic factors, regulatory factors and the need for
regulatory approval, the equity markets generally and risks
associated with growth and competition.
Although the Company has attempted to identify important factors
that could cause actual actions, events, or results to differ
materially from those described in forward-looking statements,
there may be other factors that cause actions, events, or results
to differ from those anticipated, estimated or intended. No
forward-looking statement can be guaranteed. Except as required by
applicable securities laws, forward-looking statements speak only
as of the date on which they are made and the Company undertakes no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events,
or otherwise. The reader is referred to the Company’s most recent
filings on SEDAR for a more complete discussion of all applicable
risk factors and their potential effects, copies of which may be
accessed through the Company’s profile page at www.sedar.com.
For Further Information Contact: David Hyman,
Chief Financial Officer info@rakovinatehrapeutics.com
Investor Relations & Media Ira M.
Gostinir@rakovinatherapeutics.com 775-391-0213
Rakovina Therapeutics (TSXV:RKV)
Historical Stock Chart
From Jul 2024 to Aug 2024
Rakovina Therapeutics (TSXV:RKV)
Historical Stock Chart
From Aug 2023 to Aug 2024